BIOMAT Database Logo BIOMAT Database Logo

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects. 1996

L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
Clinica delle Malattie del Sistema Nervoso, Universita di Torino, Italy.

Twenty relapsing-remitting (RR) clinically definite MS patients were treated with 9 MIU intramuscular recombinant interferon alpha-2a (rIFNA) (Roferon-A, Roche) (n = 12) or placebo (n = 8) every other day for 6 months and followed up for a further 6 months after stopping treatment. Numbers of active lesions at MRI and of patients with clinical-MRI signs of disease activity and lymphocyte interferon gamma production, which were decreased during treatment, returned to values similar to baseline and placebos after stopping treatment. rIFNA chronic therapy seems therefore needed in order to maintain drug efficacy. Side effect profile was monitored, too, for over 1 year in the same 20 patients plus 25 additional RR MS patients. Besides the typical side effects of type I interferon therapy (fever, fatigue, depression, lymphopenia, hepatic enzyme elevation), occurrence of serum autoAbs was noted in 30% patients (in 60% antinuclear and in 80% antithyroid autoAbs). In two patients rIFNA treatment was stopped, in one case for antithyroid autoAbs and hypothyroidism, in the other for antinuclear autoAbs and a five-fold increase of ALT. A careful monitoring of serum autoAbs and of signs of thyroid or liver damage must always precede and accompany longterm type I IFN therapy.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody

Related Publications

L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.
August 2006, Cancer,
L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
Long term treatment of chronic delta hepatitis with alpha recombinant interferon.
January 1991, Progress in clinical and biological research,
L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
Side effects of long-term treatment with human leukocyte interferon.
October 1979, The Journal of infectious diseases,
L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patients.
May 1989, Cancer,
L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha.
December 1992, Clinical and experimental immunology,
L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
Long-term effects of recombinant leukocyte alpha interferon in the treatment of chronic delta hepatitis.
January 1992, Archives of virology. Supplementum,
L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
[Long-term treatment of cryptogenic hepatitis C using recombinant interferon alpha].
September 1990, Zeitschrift fur Gastroenterologie,
L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
Neurological function during long-term therapy with recombinant interferon alpha.
January 1999, The Journal of neuropsychiatry and clinical neurosciences,
L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
[Long-term therapy in chronic hepatitis C with recombinant alpha interferon].
January 1994, Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques,
L Durelli, and M R Bongioanni, and B Ferrero, and D Imperiale, and E Verdun, and A Oggero, and E Gentile, and G B Bradac, and M Bergui, and L Bergamini, and B Bergamasco
Effects of recombinant alpha-2b-interferon therapy in patients with progressive MS.
June 1993, Acta neurologica Scandinavica,
Copied contents to your clipboard!